Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
· relay therapeutics, inc.
AI Briefing
- Relay Therapeutics presents positive Phase 3 data for Zovegalisib + Fulvestrant
- Data will be presented at ESMO Targeted Anticancer Therapies Congress 2026
- Phase 3 ReDiscover-2 trial initiated in mid-2025
Advertisement